You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Metastatic Castration-Resistant Prostate Cancer: Updates From the 2022 European Annual Meeting

  • Authors: A. Oliver Sartor, MD; Tanya Dorff, MD; Joe O’Sullivan, MD, FRCR, FFRCCSI, FRCPI
  • CME / ABIM MOC Released: 10/26/2022
  • Valid for credit through: 10/26/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, nuclear medicine specialists, radiologists, urologists, and other clinicians who care for patients with mCRPC.

The goal of this activity is for learners to be better able to understand the latest clinical data on mCRPC presented at the 2022 European Society of Medical Oncology (ESMO) Congress in Paris, France, and to incorporate the data into clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Key clinical trial data for the treatment of mCRPC reported at a major oncology medical meeting
  • Have greater competence related to
    • Incorporating emerging data from a major oncology medical meeting into the treatment paradigms for patients with mCRPC
  • Demonstrate greater confidence in their ability to
    • Stay abreast of evolving areas of interest for mCRPC therapies reported at a major oncology medical meeting


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • A. Oliver Sartor, MD

    Professor of Medicine
    Medical Director
    Tulane Cancer Center
    C. E. and Bernadine Laborde Professor of Cancer Research
    Tulane University, School of Medicine
    New Orleans, Louisiana

    Disclosures

    A. Oliver Sartor, MD, has the following relevant financial relationships:
    Consultant or advisor for: Advanced Accelerator Applications (AAA); Astellas Pharma, Inc.; AstraZeneca Pharmaceuticals LP; Bavarian Nordic; Bayer HealthCare; Blue Earth Diagnostics, Inc.; Bristol-Myers Squibb Company; Clarity Pharmaceuticals; Clovis Oncology; Constellation; Dendreon Corporation; EMD Serono, Inc.; Fusion; Isotopen Technologien Meunchen; Janssen Pharmaceuticals; Merck & Co., Inc.; Moyvant; Myriad; Noria Therapeutics, Inc.; Novartis Pharmaceuticals; Noxopharm; Pfizer Inc.; POINT Biopharma; Progenics Pharmaceuticals, Inc.; Sanofi; Telix; TeneoBio; Theragnostics
    Research funding from: Advanced Accelerator Applications; Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Bayer HealthCare; Constellation; Endocyte; Invitae Corporation; Janssen Pharmaceuticals; Lantheus; Merck & Co., Inc.; Progenics Pharmaceuticals, Inc.; TeneoBio
    Stock options from: AbbVie, Inc.; Cardinal Health; Clarity Pharmaceuticals; Clovis Oncology; GlaxoSmithKline; Lilly; Noria Therapeutics, Inc.; United Health Group
    Owns stock (publicly traded) in: AbbVie, Inc.; Cardinal Health; Clarity Pharmaceuticals; Clovis Oncology; GlaxoSmithKline; Lilly; Noria Therapeutics, Inc.; United Health Group

  • Tanya Dorff, MD

    Associate Professor of Medicine
    Department of Medical Oncology & Therapeutics Research
    Section Chief, Genitourinary Disease Program
    City of Hope
    Duarte, California

    Disclosures

    Tanya Dorff, MD, has the following relevant financial relationships:
    Consultant or advisor for: Astellas; AstraZeneca Pharmaceuticals LP; Exelixis, Inc.; Janssen Pharmaceuticals; Seagen Inc.

  • Joe O’Sullivan, MD, FRCR, FFRCCSI, FRCPI

    Consultant Clinical Oncologist
    Kingsbridge Private Hospital
    Clinical Professor
    Professor of Radiation Oncology
    Queen’s University Belfast
    Belfast, Ireland

    Disclosures

    Joe O’Sullivan, MD, FRCR, FFRCCSI, FRCPI, has no relevant financial relationships.

Editor

  • Davecia R. Cameron, MS

    Medical Education Director, Medscape, LLC

    Disclosures

    Davecia R. Cameron, MS, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Metastatic Castration-Resistant Prostate Cancer: Updates From the 2022 European Annual Meeting

Authors: A. Oliver Sartor, MD; Tanya Dorff, MD; Joe O’Sullivan, MD, FRCR, FFRCCSI, FRCPIFaculty and Disclosures

CME / ABIM MOC Released: 10/26/2022

Valid for credit through: 10/26/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Radiopharmaceuticals for the Management of mCRPC

Dr Sartor covers important studies presented at ESMO Congress 2022.
A. Oliver Sartor, MD

Second-Generation Antiandrogens for mCRPC

Listen to Dr Tanya Dorff discuss 3 pivotal trials on second-generation antiandrogens for mCRPC.
Tanya Dorff, MD

Novel Therapies for the Management of mCRPC

Dr Joe O’Sullivan delves into 3 important studies on mCRPC presented at ESMO Congress 2022.
Joe O’Sullivan, MD, FRCR, FFRCCSI, FRCPI